Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05012202 · ClinicalTrials.gov registry record
Validating a New Point-of-care Device for Estimation of Blood Count in Pregnant Women
A clinical trial, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- 41
- Enrollment target
NCT05012202 is a clinical trial that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 41 participants.
The verdict
NCT05012202 has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- 41 participants
- Enrollment target
Study Summary
Postpartum hemorrhage is a well-known complication of delivery and the leading cause of maternal mortality worldwide. In developed nations, a complete blood count (CBC) is commonly collected as a means to assess or base treatment for blood loss. The Hemi device is a point-of-care device designed to provide hematocrit, followed by the stage of hemorrhagic shock using artificial intelligence algorithms. The ultimate goal of the product is to provide an accurate hematocrit from easily attainable samples such as vaginal blood during hemorrhage to remove yet another barrier to access for actively bleeding women. The purpose of this study is to compare the hematocrit of vaginal blood using the Hemi device with standard venipuncture.
Interventions
- DEVICE Hemi device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2022-12-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05012202
The ClinicalTrials.gov registry entry for NCT05012202 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hemi device is the first listed.
NCT05012202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05012202 about?
NCT05012202 is a clinical study titled "Validating a New Point-of-care Device for Estimation of Blood Count in Pregnant Women". Postpartum hemorrhage is a well-known complication of delivery and the leading cause of maternal mortality worldwide. In developed nations, a complete blood count (CBC) is commonly collected as a means to assess or base treatment for blood loss. The Hemi device is a point-of-care device designed to ...
What is the current status of trial NCT05012202?
This trial is currently completed. The enrollment target is 41 participants. The study started on 2021-10-01. Estimated completion is 2022-12-10.
What interventions are being tested in trial NCT05012202?
The interventions under investigation include: Hemi device (DEVICE).
Who is sponsoring clinical trial NCT05012202?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.